{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.\n\nafatinib dimaleate: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Afatinib)"}],"populationDescription":"This outcome measure was not assessed.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Epithelial to Mesenchymal Transition States","type":"OTHER_PRE_SPECIFIED"}